132
169) Silla L, WhitesideT, Ball E. The role of natural killer cells in the treatment of
chronic myeloid leukemia. J. Hematother, 1995;4269-79.
170) Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, et
al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous
leukemia involves NKG2D-target-cell interactions Blood, 2005;106:3666-72.
171) Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from mismatched
hematopoietic transplantation Trends in Immunology, 2002;23(9)438-44.
172) Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Katia Perruccio, Urbani E.
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell
Transplantation Velardi Blood, 1999;94(1);333-9.
173) Ruggeri L, Cappanni M, Urbani E, A. Mancusi, K. Perruccio, E. Burchielli, A. et
al. Impact of natural killer cell alloreactivity on mismatched hematopoietic
transplantation, 40-49. duplicado,mesma ref 184.
174) Martelli MF, Aversa F, Lustig EB, Velardi A, Zelicher SR, Tabilio A et al. Seminars
in Hematology, 2002;39 (1)48-56.
175) Petersdorf EW, Sassazuki T, Advances in tissue typing and their potential
Impacto in GVHD Incidence and Severity. “In”: Ferrara JLM, Cooke KR, Deeg HJ.
Gravt-Vs.-Host Disease. 3
th
ed. New York: ed. Marcel Dekker, 2005:401-26.
176) Van Rod JJ, Blood HLA-C alleles1 can no longer be ignored in bone marrow
donor selection, 2004;104(7)1912-13.
177) Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al.
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell
transplantation from unrelated donors Blood, 2003;102(3);814-9.
178) Knuutila S, Larramendy ML, Ruutu T, Helande T. Involvement of Natural Killer
Cells in Chronic Myeloid Leukemia. Cancer Genet Cytogenet 1995;79:21-24.